ReAlta Life Sciences Appoints Ellen Lubman as CBO to Lead Business Development and Strategy

ReAlta Life Sciences has appointed Ellen Lubman as Chief Business Officer. Lubman has 25 years of experience in biopharmaceutical companies and a track record in strategic, transactional, and operational roles. She previously served as Chief Business Officer at Werewolf Therapeutics. Lubman will oversee business development, capital formation, and corporate strategy for ReAlta.

ReAlta Life Sciences, Inc. has announced the appointment of Ellen Lubman, MBA, as its new Chief Business Officer. Lubman brings nearly 25 years of experience in biopharmaceutical companies, with a strong track record in strategic, transactional, and operational roles. She previously served as Chief Business Officer at Werewolf Therapeutics, where she oversaw multiple financings, including an Initial Public Offering, and business development transactions [1].

In her new role at ReAlta, Lubman will oversee business development, capital formation, and corporate strategy. She will play a key leadership role in forging partnerships with pharmaceutical companies and investors to advance the company's transformative therapies for severe inflammatory diseases with high unmet need. Her appointment coincides with a pivotal moment for ReAlta, with all three of its clinical programs expected to read out this year [1].

ReAlta is a clinical mid-stage biopharmaceutical company dedicated to addressing life-threatening rare and acute inflammatory diseases by rebalancing the inflammatory response. The company's EPICC peptide platform leverages discoveries from the human astrovirus (HAstV-1), which uniquely inhibits components of the innate immune system. ReAlta's lead candidate, RLS-0071 (pegtarazimod), has received FDA Orphan Drug Designation and Fast Track Designations for several severe diseases, including hypoxic ischemic encephalopathy (HIE), acute graft-versus-host disease (aGvHD), and acute exacerbations of chronic obstructive pulmonary disease (COPD) [2].

Lubman's appointment is expected to strengthen ReAlta's management team and enhance its ability to navigate the complex biopharmaceutical landscape. Her extensive experience in the industry, coupled with her strategic and transactional expertise, positions her well to drive ReAlta's growth and success [1].

References:
[1] https://www.businesswire.com/news/home/20250725277270/en/ReAlta-Life-Sciences-Strengthens-Management-Team-with-the-Appointment-of-Biotechnology-Business-Leader-Ellen-Lubman-MBA-as-Chief-Business-Officer
[2] https://www.biospace.com/press-releases/realta-life-sciences-strengthens-management-team-with-the-appointment-of-biotechnology-business-leader-ellen-lubman-mba-as-chief-business-officer